Results of Operations and Financial Condition. On August 13, 2026 , Elicio Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2026 and provided corporate updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securi…

Entry into a Material Definitive Agreement On July 1, 2026, Elicio Therapeutics, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional investors (each an “Investor” and, collectively, the “Investors”), pursuant to which the Company agreed to issue and sell, in a registered direct offering by the Company directly to the Investors (the “Offering”) an aggregate of 4,380,313 shares (the “Shares”) of common…

Results of Operations and Financial Condition. On May 11, 2026 , Elicio Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2026 and provided corporate updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securiti…

Entry into a Material Definitive Agreement. On March 16, 2026, Elicio Therapeutics, Inc. (the “ Company ”) entered into an At Market Issuance Sales Agreement (the “ Sales Agreement ”) with B. Riley Securities, Inc., JonesTrading Institutional Services LLC and Ladenburg Thalmann & Co. Inc. (the “ Agents ”) with respect to an at-the-market offering program under which the Company may issue and sell, from time to time at its sole discretion, shares of its common stock, par value $0.01 per share…

Termination of a Material Definitive Agreement. As previously disclosed on June 3, 2024, the Company entered into a Capital on Demand™ Sales Agreement with JonesTrading Institutional Services LLC (“Jones”) as sales agent (the “Jones Sales Agreement”), pursuant to which the Company was permitted to issue and sell, from time to time through Jones, shares of the Company’s common stock having an aggregate offering price of up to $40.0 million. On March 16, 2026, the Company delivered written noti…

Results of Operations and Financial Condition. On March 12, 2026, Elicio Therapeutics, Inc. (the “Company”) announced its financial results for the year ended December 31, 2025 and provided corporate updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securit…

Results of Operations and Financial Condition. On November 13, 2025, Elicio Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2025 and provided corporate updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the…

Results of Operations and Financial Condition. On August 7, 2025, Elicio Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2025 and provided corporate updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securiti…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in

Entry into a Material Definitive Agreement. On June 3, 2025, Elicio Therapeutics, Inc. (the “Company”) entered into a note purchase agreement (the “Note Purchase Agreement”) pursuant to which the Company issued a Senior Secured Promissory Note due June 3, 2028 (the “Promissory Note”) in the principal amount of $10.0 million (the “Note Financing”). The purchaser of the Promissory Note is GKCC, LLC, an entity controlled by a member of the board of directors of the Company (the “Purchaser”). The…

Unregistered Sales of Equity Securities. The information contained above under Item 1.01, to the extent applicable, is hereby incorporated by reference herein. Based in part upon the representations of the Purchaser in the Note Purchase Agreement, the Promissory Note and Warrant were each sold in a private placement in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act. Neither the Warrant nor the Common Stock issuable on exercise thereof, have been…

Results of Operations and Financial Condition. On May 13, 2025, Elicio Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2025 and provided corporate updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securitie…

Results of Operations and Financial Condition. On March 31, 2025, Elicio Therapeutics, Inc. (the “Company”) announced its financial results for the year ended December 31, 2024 and provided corporate updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securit…

Chief Strategy and Financial Officer, Principal Financial Officer, Principal Accounting Officer — Preetam Shah, Ph.D., M.B.A.: Dr. Preetam Shah was appointed as the Chief Strategy and Financial Officer, and will also serve as Principal Financial Officer and Principal Accounting Officer.

Unregistered Sales of Equity Securities. As previously disclosed, on August 12, 2024, Elicio Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement pursuant to which the Company issued a 3.0% Senior Secured Convertible Promissory Note due February 15, 2026 (the “Convertible Note”) in the principal amount of $20.0 million to GKCC, LLC, an entity controlled by a member of the board of directors of the Company (the “Purchaser”). Under the terms of the Convertible Note, i…

Entry into a Material Definitive Agreement On January 29, 2025, Elicio Therapeutics, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional investors (each an “Investor” and, collectively, the “Investors”), pursuant to which the Company agreed to issue and sell, in a registered direct offering by the Company directly to the Investors (the “Offering”): (i) an aggregate of 1,261,830 shares (the “Shares”) o…

Results of Operations and Financial Condition. On November 13, 2024, Elicio Therapeutics, Inc. (the "Company") announced its financial results for the quarter ended September 30, 2024 and provided corporate updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the…

Principal Accounting Officer and Principal Financial Officer — Robert Connelly: Robert Connelly was appointed as the Principal Accounting Officer and Principal Financial Officer.

Chief Financial Officer and Treasurer — Brian Piekos: Mr. Piekos resigned to pursue another opportunity.

Results of Operations and Financial Condition. On August 13, 2024, Elicio Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2024 and provided corporate updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securit…

Entry into a Material Definitive Agreement. On August 12, 2024, Elicio Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) pursuant to which the Company issued a 3.0% Senior Secured Convertible Promissory Note due February 15, 2026 (the “Convertible Note”) in the principal amount of $20.0 million (the “Note Financing”). The purchaser of the Convertible Note is GKCC, LLC, an entity controlled by a member of the board of director…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in

Unregistered Sales of Equity Securities. The information contained above under Item 1.01, to the extent applicable, is hereby incorporated by reference herein. Based in part upon the representations of the Purchaser in the Securities Purchase Agreement, the Convertible Note was sold in a private placement in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act. Neither the Convertible Note nor the Common Stock issuable on conversion thereof have been r…

Other Events On June 28, 2024, the Company issued a press release (the “Pricing Press Release”) announcing the pricing of the Offering. A copy of the Pricing Press Release is attached hereto as Exhibit 99.1 and is incorporated by reference herein. Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the closing o…

Entry into a Material Definitive Agreement. On June 28, 2024, Elicio Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with JonesTrading Institutional Services LLC, as the representative of the several underwriters named in Schedule I thereto (collectively, the “Underwriters”), relating to an underwritten offering (the “Offering”) of (i) 500,000 shares (the “Shares”) of the Company’s common stock, $0.01 par value per share (the “Common St…